China's medical products regulator granted Sihuan Pharmaceutical (HKG:0460) subsidiary Meiyan Space Biological Technology (Jilin) class 3 medical device approval for its injectable polycaprolactone microsphere facial filler.
The filler is a regenerative material that helps address facial contour deficiencies and corrects wrinkles in between the nose and lips, according to a Wednesday filing with the Hong Kong bourse.
Shares in the aesthetic product company fell 3% during afternoon trading on Thursday.